Drugs / MK-8435
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00725075 | Apr 2007 → Oct 2008 | schizophrenia | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00725075 ↗ |
| Known as | Org 25935 | “MK-8435 (Org 25935) is an investigational drug that may help to correct the above characteristics of schizophrenia” NCT00725075 ↗ |
| Route | Oral | “Administered orally 2 times a day (BID)” NCT00725075 ↗ |